PriceTargets.com logo

Gritstone bio - GRTS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $2.17
  • Forecasted Upside: ∞
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$0.00 As of 10/21/2024 10:03 PM ET
+0 (0.00%)
Get New Gritstone bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRTS

Analyst Price Target is $2.17
▲ +∞ Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Gritstone bio in the last 3 months. The average price target is $2.17, with a high forecast of $5.00 and a low forecast of $0.50. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for GRTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 contributing investment analysts is to moderate buy stock in Gritstone bio. This rating has held steady since September 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/2/2024B. RileyReiterated RatingBuy ➝ Neutral$3.00 ➝ $1.00
10/1/2024Evercore ISIUpgradeStrong-Buy
10/1/2024B. RileyDowngradeStrong-Buy ➝ Hold
10/1/2024HC WainwrightReiterated RatingBuy ➝ Neutral$4.00 ➝ $0.50
10/1/2024JMP SecuritiesDowngradeOutperform ➝ Market Perform
8/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
8/5/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.00
8/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
6/14/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.00
5/24/2024B. RileyReiterated RatingBuy ➝ Buy$6.00 ➝ $3.00
5/13/2024HC WainwrightLower TargetBuy ➝ Buy$7.00 ➝ $4.00
4/2/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$4.00 ➝ $5.00
3/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00
2/28/2024JMP SecuritiesInitiated CoverageMkt Outperform$4.00
9/28/2023Piper SandlerBoost TargetOverweight ➝ Overweight$6.00 ➝ $7.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$7.00
3/31/2023Evercore ISIInitiated CoverageOutperform
3/28/2023B. RileyInitiated CoverageBuy$8.00
3/14/2023HC WainwrightReiterated RatingBuy$7.00
2/15/2023HC WainwrightReiterated RatingBuy$7.00
11/7/2022HC WainwrightLower TargetBuy$12.00 ➝ $7.00
10/30/2022Piper SandlerInitiated CoverageOverweight$6.00
8/22/2022The Goldman Sachs GroupDowngradeNeutral ➝ Sell$2.00
5/9/2022HC WainwrightLower Target$15.00 ➝ $12.00
3/14/2022HC WainwrightLower TargetBuy$24.00 ➝ $15.00
9/20/2021HC WainwrightReiterated RatingBuy$24.00
8/10/2021HC WainwrightReiterated RatingBuy$24.00
1/21/2021BTIG ResearchBoost TargetBuy$17.00 ➝ $35.00
1/20/2021HC WainwrightBoost TargetBuy$16.00 ➝ $24.00
1/20/2021Robert W. BairdDowngradeOutperform ➝ Underperform$8.00
8/6/2020HC WainwrightReiterated RatingBuy$16.00
7/14/2020BTIG ResearchLower TargetPositive ➝ Buy$31.00 ➝ $17.00
3/12/2020HC WainwrightReiterated RatingBuy
1/15/2020CowenReiterated RatingBuy
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 41 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 64 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 2 very positive mentions
  • 41 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Gritstone bio logo
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.35
Low: $0.03
High: $0.63

52 Week Range

Now: N/A

Volume

61,017,902 shs

Average Volume

7,014,435 shs

Market Capitalization

$3.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Gritstone bio?

The following Wall Street analysts have issued research reports on Gritstone bio in the last twelve months: B. Riley, Evercore ISI, HC Wainwright, and JMP Securities.
View the latest analyst ratings for GRTS.

What is the current price target for Gritstone bio?

0 Wall Street analysts have set twelve-month price targets for Gritstone bio in the last year. Their average twelve-month price target is $2.17. JMP Securities has the highest price target set, predicting GRTS will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $0.50 for Gritstone bio in the next year.
View the latest price targets for GRTS.

What is the current consensus analyst rating for Gritstone bio?

Gritstone bio currently has 3 hold ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for GRTS.

What other companies compete with Gritstone bio?

Other companies that are similar to Gritstone bio include Acurx Pharmaceuticals, TherapeuticsMD, HCW Biologics, Marinus Pharmaceuticals and PharmaCyte Biotech. Learn More about companies similar to Gritstone bio.

How do I contact Gritstone bio's investor relations team?

Gritstone bio's physical mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company's listed phone number is (510) 871-6100 and its investor relations email address is [email protected]. The official website for Gritstone bio is www.gritstoneoncology.com. Learn More about contacing Gritstone bio investor relations.